The content on this site is intended for healthcare professionals only
Dr Josep Tabernero speaks to ecancer about the final analysis of the phase III KRYSTAL-10 trial evaluating adagrasib plus cetuximab as second-line treatment for KRAS G12C-mutated metastatic colorectal cancer.
The study found that the chemotherapy-free combination did not significantly improve progression-free or overall survival compared with chemotherapy. However, it produced a higher objective response rate, including more complete responses, with manageable safety and no new safety signals.
Dr Tabernero discusses the clinical activity of the regimen and its potential role in previously treated patients.
Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours
Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer
Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma
Daraxonrasib nearly doubles survival in previously treated metastatic pancreatic cancer
Abemaciclib shows benefit in dedifferentiated liposarcoma
Neoadjuvant chemoradiotherapy plus sintilimab improves pCR in resectable locally advanced oesophageal squamous cell carcinoma
The potential of T-cell engagers in SCLC treatment
Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer
ASCO 2025: Latest in EGFR positive NSCLC
